ArticlePloS one2025
Improving Parkinson's disease management through wearable technology: A cost-benefit perspective.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Digital Gait Biomarkers for Parkinson's Disease: Subject-Wise Validated Explainable AI Framework Using Vertical Ground Reaction Force Signals.Bioengineering (Basel, Switzerland) · 2026Article
- Mapping the global landscape of wearable devices in healthcare: A dual-database bibliometric analysis (2016-2026).Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's Disease (PD) is a progressive neurodegenerative disorder affecting millions of patients worldwide, with significant economic and social implications. The increasing prevalence of PD, coupled with rising healthcare costs, necessitates cost-effective solutions for patient management. Wearable medical devices, such as STAT-ON™, an inertial sensor with AI processing capability, offer an opportunity to enhance symptom monitoring, optimize therapy adjustments, and improve patient quality of life (QoL). However, their cost-effectiveness in routine clinical practice remains insufficiently explored. This study conducts a cost-benefit analysis of integrating STAT-ON™ into European healthcare systems (Spain, Sweden, Germany, Italy, and the UK). Using validated clinical data, we assess the economic impact of early symptom detection facilitated by continuous monitoring. Our findings suggest that improved symptom assessment can lead to optimized medication regimens, reducing hospitalizations and institutional care costs. While medication costs may increase, overall direct healthcare expenses decrease, leading to net savings. As an example, the study estimates potential cost reductions of up to €137.8 million in Germany and €19 million in Sweden when STAT-ON™ is used to detect advanced PD symptoms. Despite these promising results, limitations exist, including variations in healthcare costs, reimbursement policies, and real-world adoption rates across the different countries. Additionally, indirect costs such as caregiver burden were not fully analyzed. Future longitudinal studies are needed to further validate the economic and clinical benefits of wearable monitoring devices in PD management. This study highlights the potential of STAT-ON™ as a valuable tool for reducing healthcare costs and enhancing patient outcomes, supporting its adoption as a complementary solution for objective PD assessment in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.